ARTICLE
5 March 2026

Update On Proposed Ministerial Reliance Order

SB
Smart & Biggar

Contributor

Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients. Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights. As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
As we reported last month, the Minister of Health launched a consultation on a proposed Ministerial Reliance Order that would permit Health Canada to complete the examination of certain parts...
Canada Food, Drugs, Healthcare, Life Sciences
Urszula Wojtyra’s articles from Smart & Biggar are most popular:
  • within Food, Drugs, Healthcare and Life Sciences topic(s)
  • in India

As we reported last month, the Minister of Health launched a consultation on a proposed Ministerial Reliance Order that would permit Health Canada to complete the examination of certain parts of a drug submission for new drugs by relying on decisions and documents made by foreign trusted regulators.

Health Canada has issued additional information for stakeholders regarding the proposed Ministerial Reliance Order. The additional information is intended to complement the draft Reliance Order and provides general information on how Health Canada proposes to interpret the requirements in the draft Reliance Order.

Further, the end of the consultation period has been extended to March 14, 2026.

Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group or the Pharmaceutical Litigation Group.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More